Trial Profile

A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Nov 2024 According to a QuarAlis Corporation media release, Cohorts 1 and 2 have successfully completed dosing and an amendment to the DRF study design has been approved in Canada and the UK, with anticipated approval from the EU in the near future.
19 Nov 2024 According to a QuarAlis Corporation media release, Company to present update at 35th International Symposium on ALS/MND.
19 Nov 2024 According to a QuarAlis Corporation media release, ANQUR protocol amended to include additional biomarkers and cohort of participants with C9orf72-related ALS.The study design will now also include a cohort of participants with C9orf72-related ALS in addition to participants with sporadic ALS.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com